Improving HCV Screening in Addiction Care Centers with Plasma Separation Cards
Velásquez Orozco, Fernando (Hospital del Mar (Barcelona, Catalunya))
Tabernero, David (Hospital Universitari Vall d'Hebron)
Barbaglia, María Gabriela (Institut de Recerca Sant Pau)
Treviño, L. (CAS Garbivent)
Trujillo, B. (CAS Garbivent)
Marco Valle, Alberto (Instituto de Salud Carlos III)
Carrillo, M.Á. (CAS Nou Barris)
Ruiz Salinas, Gerard (Hospital Universitari Vall d'Hebron)
Majo Roca, F.X. (Generalitat de Catalunya)
Colom Farran, J. (Generalitat de Catalunya)
Buti, Maria (Hospital Universitari Vall d'Hebron)
Pumarola Suñé, Tomàs (Hospital Universitari Vall d'Hebron)
Rodriguez-Frias, F. (Universitat Internacional de Catalunya)
Rando-Segura, Ariadna (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Data:	2025
Resum:	Globally, 50 million people are infected with hepatitis C virus (HCV), many of whom are people who inject drugs. These individuals face healthcare barriers, necessitating innovative diagnostic tools. This study evaluated the impact of cobas plasma separation cards (PSCs) for dry plasma collection in Barcelona's outpatient drug addiction centers (CAS). From February to December 2021, nine CASs were invited to implement PSC for HCV screening; three centers participated, allowing for the assessment of its impact on HCV detection. Of the 679 clients screened, 54 (8%) provided finger-prick blood samples via PSC due to their refusal or inability to undergo venipuncture. Overall, 100 (14. 7%) clients tested positive for HCV antibodies, with 24 (24%) confirmed as HCV-RNA positive. Among venipuncture clients, 9. 1% had positive antibodies, with 15. 8% showing active infection. In contrast, 79. 6% of PSC clients had positive antibodies and 34. 9% had detectable HCV RNA, contributing to 62. 5% of the active infections detected. The odds ratio was 26. 3, indicating that refusal or inability to undergo venipuncture correlated with a significantly higher burden of active HCV infection. The findings highlight PSC as a valuable alternative for diagnosing HCV in people with substance use disorders, addressing accessibility barriers and improving linkage to care in high-risk populations.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Finger prick ; Hepatitis c infection ; Intravenous drug users
Publicat a:	Pathogens, Vol. 14 Núm. 3 (march 2025) , p. 239, ISSN 2076-0817

DOI: 10.3390/pathogens14030239
PMID: 40137724

9 p, 525.3 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats